The study included individuals with diabetes, no prior NAION history, and a semaglutide prescription, comparing them to a control group on nonGLP1 RA antidiabetic medications
That translates to roughly 52 pounds for a 230-pound patient
[3] [4] These studies demonstrated that combination therapy can produce greater weight loss than monotherapy, supporting the general concept that complementary mechanisms may enhance outcomes
These thermoregulatory changes are typically temporary and may improve as weight stabilizes and the body adapts to its new composition
The exception is when using very high, advanced doses of metabolic peptides, where a larger individual may need the upper end of the range
Key Takeaways Tirzepatide and semaglutide are both once-weekly injectable medications for diabetes and weight management, but tirzepatide targets both GLP-1 and GIP receptors while semaglutide targets only GLP-1